Search tips
Search criteria 


Logo of molmedLink to Publisher's site
Mol Med. 1998 October; 4(10): 671–674.
PMCID: PMC2230253

No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus.


BACKGROUND: Allelic association case-control analysis of a deletion/insertion polymorphism in the serotonin transporter-linked polymorphic region (5-HTTLPR) has suggested associations with unipolar disorder, bipolar disorder, depression, and Alzheimer's disease. Moreover, the heterozygous long form of the 5-HTTLPR has been associated with increased levels of mRNA for the serotonin transporter (5-HTT) and increased serotonin uptake in lymphoblastic cell lines. This study attempts to determine whether there is an association between 5-HTTLPR genotype and schizophrenia or the binding of [3H]paroxetine to the human hippocampal 5-HTT. MATERIALS AND METHODS: DNA from the cerebellum from 58 schizophrenic and 62 control subjects was used to genotype the 5-HTTLPR. In addition, the relationship between 5-HTTLPR genotype and the affinity and density of [3H]paroxetine binding to the hippocampal 5-HTT was assessed. RESULTS: There were no associations between 5-HTTLPR allotype or genotype and/or the parameters of [3H]paroxetine binding to the hippocampal 5-HTT. CONCLUSIONS: Our data suggest that 5-HTTLPR genotype neither confers an increased susceptibility for schizophrenia nor dictates the expression of the 5-HTT in the human hippocampus.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (558K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N, Copolov DL. [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem. 1995 Mar;64(3):1197–1202. [PubMed]
  • Naylor L, Dean B, Opeskin K, Pavey G, Hill C, Keks N, Copolov D. Changes in the serotonin transporter in the hippocampus of subjects with schizophrenia identified using [3H]paroxetine. J Neural Transm. 1996;103(6):749–757. [PubMed]
  • Kendler KS, Diehl SR. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull. 1993;19(2):261–285. [PubMed]
  • Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, Riederer P. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95(2):157–162. [PubMed]
  • Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, Easton DF, Rubinsztein DC. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet. 1998 Feb 7;81(1):58–63. [PubMed]
  • Collier DA, Stöber G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996 Dec;1(6):453–460. [PubMed]
  • Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov 29;274(5292):1527–1531. [PubMed]
  • Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S, Collier D. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Neuroreport. 1997 Feb 10;8(3):683–686. [PubMed]
  • Mendes de Oliveira JR, Otto PA, Vallada H, Lauriano V, Elkis H, Lafer B, Vasquez L, Gentil V, Passos-Bueno MR, Zatz M. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am J Med Genet. 1998 May 8;81(3):225–227. [PubMed]
  • Stöber G, Jatzke S, Heils A, Jungkunz G, Fuchs E, Knapp M, Riederer P, Lesch KP. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur Arch Psychiatry Clin Neurosci. 1998;248(2):82–86. [PubMed]
  • Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry Suppl. 1989 Dec;(8):25–31. [PubMed]
  • Hill C, Keks N, Roberts S, Opeskin K, Dean B, MacKinnon A, Copolov D. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry. 1996 Apr;153(4):533–537. [PubMed]
  • Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics. 1997 Dec;53(4):1253–1261. [PubMed]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ